Michael D. Blaszyk net worth and biography

Michael Blaszyk Biography and Net Worth

Michael D. Blaszyk has served as a member of the Board since July 2015. Since July 2017, Mr. Blaszyk has served as an operating partner of Beecken Petty O’Keefe & Company, LLC (BPOC), a capital markets company. Prior to BPOC, he served as the chief financial officer and chief corporate officer of Dignity Health (formerly known as Catholic Healthcare West), a not-for-profit public benefit corporation, from December 2000 until his retirement in December 2015. Prior to joining Dignity Health, he served as the senior vice president and chief financial officer of University Hospitals Health System in Cleveland, Ohio, a healthcare system, from 1997 to 2000. He also previously served as the managing partner of the Northeast Region Health Care Provider Consulting Practice for Mercer LLC (formerly known as William M. Mercer), a global consulting firm, and the executive vice president of Boston Medical Center, a not-for-profit academic medical center. Mr. Blaszyk is a director/manager for Medicus, NantHealth (an affiliate of Dr. Soon-Shiong), Himagine, and Health Management Associates. He received his B.S. in Life Sciences from Wayne State University and his Masters in Health Administration from the University of Colorado. We believe Mr. Blaszyk is qualified to serve as a member of the Board based on his extensive experience with and knowledge of the healthcare industry and his significant financial and accounting background.

What is Michael D. Blaszyk's net worth?: The estimated net worth of Michael D. Blaszyk is at least $528,575.25 as of June 5th, 2023. Mr. Blaszyk owns 71,915 shares of ImmunityBio stock worth more than $528,575 as of April 27th. This net worth evaluation does not reflect any other assets that Mr. Blaszyk may own. Learn More about Michael D. Blaszyk's net worth.
How do I contact Michael D. Blaszyk?: The corporate mailing address for Mr. Blaszyk and other ImmunityBio executives is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. ImmunityBio can also be reached via phone at (858) 633-0300 and via email at [email protected]. Learn More on Michael D. Blaszyk's contact information.
Has Michael D. Blaszyk been buying or selling shares of ImmunityBio?: Michael D. Blaszyk has not been actively trading shares of ImmunityBio during the last quarter. Most recently, on Monday, June 5th, Michael D. Blaszyk bought 71,915 shares of ImmunityBio stock. The stock was acquired at an average cost of $2.75 per share, with a total value of $197,766.25. Following the completion of the transaction, the director now directly owns 71,915 shares of the company's stock, valued at $197,766.25. Learn More on Michael D. Blaszyk's trading history.
Who are ImmunityBio's active insiders?: ImmunityBio's insider roster includes Richard Adcock (CEO), Michael Blaszyk (Director), Cheryl Cohen (Director), David Sachs (CFO), and Barry Simon (Director). Learn More on ImmunityBio's active insiders.
Are insiders buying or selling shares of ImmunityBio?: In the last year, ImmunityBio insiders bought shares 2 times. They purchased a total of 96,915 shares worth more than $268,516.25. The most recent insider tranaction occured on June, 5th when Director Michael D Blaszyk bought 71,915 shares worth more than $197,766.25. Insiders at ImmunityBio own 83.4% of the company. Learn More about insider trades at ImmunityBio.
Information on this page was last updated on 6/5/2023.

Michael D. Blaszyk Insider Trading History at ImmunityBio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/5/2023	Buy	71,915	$2.75	$197,766.25	71,915

Michael D. Blaszyk Buying and Selling Activity at ImmunityBio

ImmunityBio Company Overview

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies. Its lead biologic commercial product candidate is Anktiva, an IL-15 superagonist antibody-cytokine fusion protein for the treatment of bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease. The company also develops other therapeutic agents for the treatment of liquid and solid tumors, including bladder, lung, colorectal, and ovarian cancers, as well as glioblastoma multiforme, acute myeloid leukemia, and human immunodeficiency virus. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., and Viracta Therapeutics, Inc. The company is based in San Diego, California.

Today's Range

Now: $7.35

$4.92

$7.74

50 Day Range

MA: $5.25

$3.50

$7.35

2 Week Range

Now: $7.35

$1.25

$7.74

Volume

40,280,221 shs

Average Volume

5,620,171 shs

Market Capitalization

$4.98 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>